Krystal Biotech, Inc. Share Price
KRYSKrystal Biotech, Inc. Stock Performance
Open $256.72 | Prev. Close $258.65 | Circuit Range N/A |
Day Range $256.41 - $258.67 | Year Range $122.80 - $297.85 | Volume 5,261 |
Average Traded $257.78 |
Krystal Biotech, Inc. Share Price Chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
08-Apr-26 | $270.67 | $264.14 | +0.11% |
07-Apr-26 | $259.72 | $263.84 | +0.86% |
06-Apr-26 | $263.45 | $261.60 | +0.30% |
02-Apr-26 | $255.81 | $260.82 | +0.63% |
01-Apr-26 | $258.50 | $259.19 | +0.54% |
31-Mar-26 | $256.29 | $257.81 | +4.55% |
30-Mar-26 | $246.20 | $246.60 | -0.63% |